Rsvpref3 Antigen/As01e/Pf
Brand names: Arexvy
At a glance
- Medicare prescriptions, 2024
- 2,687,127
- Medicare drug cost
- $733.1M
- Average cost per prescription
- $273
- Clinicians who prescribed it
- 25,021
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
No FDA prescription label was found for this drug name.
Who prescribes it
- Family Medicine 40.3%
- Pharmacists 20.6%
- Internal Medicine 17.3%
- Emergency Medicine 6.4%
- Hospitalist 4.1%
- ENT (Otolaryngology) 2.2%
- OB-GYN (Obstetrics & Gynecology) 1.8%
- Cardiology 1.6%
- Occupational Medicine 1.6%
- Nurse Practitioners 1.2%
- General Practice 0.5%
- Geriatric Medicine 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Industry payments about this drug
Drug makers reported $2.3M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- GlaxoSmithKline, LLC. $2.3M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.